Progyny, Inc. (PGNY)
| Market Cap | 2.70B +27.7% |
| Revenue (ttm) | 1.34B +5.5% |
| Net Income | 91.02M +60.9% |
| EPS | 1.08 +74.8% |
| Shares Out | 73.65M |
| PE Ratio | 34.03 |
| Forward PE | 15.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 909,185 |
| Open | 36.97 |
| Previous Close | 37.15 |
| Day's Range | 36.49 - 37.20 |
| 52-Week Range | 16.10 - 37.20 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 37.75 (+2.83%) |
| Earnings Date | Nov 4, 2026 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PGNY stock is "Strong Buy." The 12-month stock price target is $37.75, which is an increase of 2.83% from the latest price.
News
Progyny price target raised to $42 from $36 at Truist
Truist raised the firm’s price target on Progyny (PGNY) to $42 from $36 and keeps a Buy rating on the shares. The firm notes that its updated forecasts imply revenue…
Progyny price target raised to $42 from $36 at Truist
Truist raised the firm’s price target on Progyny (PGNY) to $42 from $36 and keeps a Buy rating on the shares. The firm increased its FY27/FY28 revenue and adjusted EBITDA…
Progyny price target raised to $37 from $30 at Barclays
Barclays analyst Peter Warendorf raised the firm’s price target on Progyny (PGNY) to $37 from $30 and keeps an Equal Weight rating on the shares.
Progyny price target raised to $35 from $30 at JPMorgan
JPMorgan raised the firm’s price target on Progyny (PGNY) to $35 from $30 and keeps a Neutral rating on the shares.
Progyny price target raised to $36 from $31 at BofA
BofA analyst Allen Lutz raised the firm’s price target on Progyny (PGNY) to $36 from $31 and keeps a Buy rating on the shares after what the firm calls a…
Progyny price target raised to $35 from $31 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Progyny (PGNY) to $35 from $31 and keeps an Overweight rating on the shares. Progyny’s record 2027 selling season and third guidance…
Progyny price target raised to $36 from $35 at Canaccord
Canaccord raised the firm’s price target on Progyny (PGNY) to $36 from $35 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results…
Progyny price target raised to $38 from $37 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Progyny (PGNY) to $38 from $37 and keeps an Overweight rating on the shares. A record selling season of…
Progyny price target raised to $38 from $33 at Citizens
Citizens analyst Constantine Davides raised the firm’s price target on Progyny (PGNY) to $38 from $33 and keeps an Outperform rating on the shares.
Progyny Earnings Call Transcript: Q3 2026
Q3 set revenue and profitability records, with strong cash generation and a raised FY 2026 guidance midpoint. A record selling season added 1.3 million lives and more than 85 clients, supporting a strong 2027 pipeline.
Progyny Earnings release: Q3 2026
Progyny released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Progyny Quarterly report: Q3 2026
Progyny has published its Q3 2026 quarterly earnings report on November 4, 2026.
Progyny Slides: Q3 2026
Progyny has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Progyny sees Q4 adjusted EPS 53c-58c, consensus 53c
Sees Q4 revenue $344.7M-$364.7M, consensus $355.23M. Sees Q4 adjusted EBITDA $57.9M-$62.9M.
Progyny raises Fy26 adjusted EPS view to $2.09-$2.13 from $2.04-$2.10
Consensus $2.08. Narrows FY26 revenue view to $1.27B-$1.39B from $1.36B-$1.39B, consensus $1.37B. Narrows FY26 adjusted EBITDA view to $235M-$240M from $233M-$240M. “We achieved strong top- and bottom...
Progyny reports Q3 adjusted EPS 53c, consensus 51c
Reports Q3 revenue $341.25M, consensus $340.76M. “We’re exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 ...
Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises...
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care Research presented at ASRM...
New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study s...
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period en...
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating ...
Progyny covered lives outlook ‘clear positive,’ says Leerink
Leerink analyst Michael Cherny views Progyny’s (PGNY) announcement this morning of 1.2M new covered lives from launches throughout the first half of 2027 as a “clear positive.” As Progyny ramps…
Progyny says selling season pacing to ‘record’ level
Progyny (PGNY) earlier revealed insights from the company’s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribu...
Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Deliver...
Progyny Transcript: Wells Fargo 21st Annual Healthcare Conference
Seasonal utilization softness was noted but is seen as normal, with stable demand expected for the year. Growth is driven by expanding market acceptance, new risk-based products for smaller employers, and ongoing cost containment. Early commitments support confidence in meeting the one million lives target.